Ticker League

Estimates for Incyte (INCY)

Analyst consensus revenue & EPS estimates for Incyte (INCY) — Q2 2026. Compare the numbers and make your own prediction.

Consensus EPS · Q2 2026

$2.09

Consensus revenue · Q2 2026

$1.5B

Analysts

13

Expected report

Jul 28, 2026

Before open
Upcoming earnings
Locks in 4 days 4 hours · BMO: Locks 8:00 PM ET previous day
Revenue$1.5B$1.3B $1.6B
EPS$2.09$1.51 $2.84

What to watch

  • Analyst ratings: Mixed
Make your prediction

Analyst consensus

Based on estimates from 13 analysts.

  • Revenue$1.5B
  • EPS$2.09
  • EBITDA$316.1M
  • EBIT$286.5M
  • Net income$444.6M

Historical beat/miss

Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.

  • Q1 2026+4.7%+35.1%

Estimate revisions

How analyst consensus estimates have changed over the past 90 days.

Collecting data

Revision trends appear once we have collected at least two daily snapshots for this period.

Community vs analysts

See how the TickerLeague crowd's forecast stacks up against Wall Street.

Be the first to predict

No community consensus for Incyte (INCY) Q2 2026 yet. Make a prediction to start the crowd forecast.

Make your prediction

Analyst price target

Based on price targets from 4 analysts.

Low
$99.00
Consensus
$113.09
Median
$110.00
High
$140.00
Current
$115.79
Upside
-2.3%

Upside calculated vs most recent trading price of $115.79.

Consensus across all covering analysts. See the ranking ›

$113.09-2.33%

Analyst ratings

Consensus: Buy — based on 44 analyst ratings.

Buy 23Hold 20Sell 1

24-month trend

Recent analyst actions

  • Jul 21, 2026HC Wainwright & Co.Buy
  • Jul 14, 2026BarclaysOverweight
  • Jul 13, 2026BMO CapitalMarket Perform
  • Jul 7, 2026RBC CapitalSector Perform
  • Jun 29, 2026HC Wainwright & Co.Buy
  • Jun 26, 2026UBSNeutral
  • Jun 24, 2026HC Wainwright & Co.Buy
  • Jun 22, 2026Truist SecuritiesHold
  • Jun 22, 2026BMO CapitalMarket Perform
  • Jun 9, 2026HC Wainwright & Co.Buy

Frequently asked questions

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation